BioSig Technologies, a company listed on NASDAQ (ticker: BSGM), saw its stock price rise by 30% during pre-market trading after it announced a big financial deal with Streamex Exchange. The agreement could provide up to $1.1 billion in funding to help grow the business.
Here’s what the deal includes:
- $100 million in secured convertible debentures: These are special types of loans that can later be converted into company shares. Out of this, $75 million is being raised now, and $25 million will come later.
- $1 billion equity line of credit: This means BioSig can raise money by selling company shares to Streamex over time, as needed. This part of the deal is expected to be finalized by October 7, 2025.
- The debentures have a 2-year maturity and will earn 4% yearly interest until converted or paid back.
Purpose of the funding:
- The money will be used to launch a gold-backed treasury system, which means the company will use real gold to back its financial activities.
- It will also help them expand into real-world asset tokenization — converting physical assets like commodities (gold, oil, etc.) into digital tokens on the blockchain.
Why it matters:
- BioSig recently merged with Streamex, giving it a strong position in both finance and blockchain technology.
- Streamex has a unique blockchain platform built with Solana, and together, they aim to bring the massive $142 trillion global commodities market onto the blockchain.
- This move could make them one of the largest public gold holders and major players in digital asset innovation.
About BioSig Technologies
BioSig Technologies is advancing cardiac care through superior signal processing
BioSig is a med‑tech company dedicated to interpreting the body’s electrical signals—primarily those of the heart—using its FDA-cleared PURE EP™ Platform. This cutting‑edge solution combines both hardware and software to deliver intracardiac signal recordings with exceptional clarity, free from noise, saturation, or interference.
Mission and Vision
The company’s core aim is to elevate cardiac treatment standards by giving electrophysiologists clearer, more reliable signal data. Their vision reflects a physician-driven ethos: creating tools that yield sharper insights and pave the way for innovative arrhythmia therapies.
Technological Edge
At the heart of their offering is the PURE EP™ Platform—a digital signal processing system that records full-spectrum intracardiac data. It provides real-time, high-fidelity views of electrograms (EGMs), enabling precise and efficient cardiac ablation procedures that other systems can’t match.
Core Values
BioSig emphasizes authenticity, integrity, passion, grit, respect, and ethical success. These values guide the company’s transparent communication, accountability, deep-seated enthusiasm for its work, resilience through long-term challenges, respect for collaboration, and purpose-driven growth.
Culture and Leadership
Leadership brings decades of multidisciplinary experience, fostering a mission-aligned and sustainable growth culture. BioSig positions itself as a place for professionals- engineers, clinicians, researchers- to collaborate on meaningful healthcare innovations.
Commitment to Innovation
The PURE EP™ Platform is configurable and equipped with custom algorithms and advanced signal-cleaning tools. It enables deep exploration of intracardiac studies, unlocking operational, clinical, and economic benefits by expanding procedural capabilities.
Partnerships
BioSig entered a 10-year strategic alliance with Mayo Clinic in 2017, aiming to co-develop advanced features, explore new applications, and file shared patents. It also collaborates with Sherpa Technology Group for IP strategy and Plexus Corp for robust engineering and manufacturing capabilities.
Why It Matters
By delivering enhanced signal fidelity, BioSig empowers physicians with actionable insights to increase the precision, safety, and effectiveness of cardiac ablations—ultimately benefiting patients and healthcare systems as a whole.
